Spero Therapeutics (SPRO) EBITDA (2015 - 2026)
Spero Therapeutics (SPRO) EBITDA from Dec 31, 2015 to Mar 31, 2026. The TTM Spero Therapeutics (SPRO) EBITDA is $13M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
Annual EBITDA change of Spero Therapeutics (SPRO)
| Year | EBITDA | Change |
|---|---|---|
| 2026 | -$7.20M | -214.10% |
| 2025 | $6.31M | -108.60% |
| 2024 | -$73M | -435.74% |
| 2023 | $22M | -152.87% |
| 2022 | -$41M | -52.67% |
| 2021 | -$87M | +11.45% |
| 2020 | -$78M | +25.42% |
| 2019 | -$62M | +47.33% |
| 2018 | -$42M | +2.49% |
| 2017 | -$41M | +25.59% |
| 2016 | -$33M | +147.30% |
| 2015 | -$13M | N/A |